Driehaus Capital Management LLC Sells 26,993 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

Driehaus Capital Management LLC lowered its stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) by 26.0% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 76,650 shares of the company’s stock after selling 26,993 shares during the quarter. Driehaus Capital Management LLC owned approximately 0.10% of SpringWorks Therapeutics worth $2,887,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of SWTX. SG Americas Securities LLC raised its stake in shares of SpringWorks Therapeutics by 8.3% during the 1st quarter. SG Americas Securities LLC now owns 4,673 shares of the company’s stock worth $230,000 after purchasing an additional 358 shares in the last quarter. Profund Advisors LLC grew its position in shares of SpringWorks Therapeutics by 1.3% in the 2nd quarter. Profund Advisors LLC now owns 29,048 shares of the company’s stock valued at $1,094,000 after acquiring an additional 362 shares during the period. First Horizon Advisors Inc. increased its stake in shares of SpringWorks Therapeutics by 47.9% during the 2nd quarter. First Horizon Advisors Inc. now owns 1,183 shares of the company’s stock worth $45,000 after purchasing an additional 383 shares during the last quarter. American International Group Inc. raised its holdings in shares of SpringWorks Therapeutics by 1.2% in the 1st quarter. American International Group Inc. now owns 33,751 shares of the company’s stock valued at $1,661,000 after purchasing an additional 394 shares during the period. Finally, CANADA LIFE ASSURANCE Co lifted its stake in SpringWorks Therapeutics by 20.3% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 4,465 shares of the company’s stock valued at $220,000 after purchasing an additional 754 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on SWTX shares. Wedbush reissued an “outperform” rating and set a $77.00 price target (up previously from $75.00) on shares of SpringWorks Therapeutics in a research report on Wednesday, August 28th. HC Wainwright reissued a “buy” rating and set a $76.00 target price on shares of SpringWorks Therapeutics in a report on Wednesday, August 28th. Finally, JPMorgan Chase & Co. raised their price target on SpringWorks Therapeutics from $64.00 to $68.00 and gave the company an “overweight” rating in a report on Wednesday, September 4th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $68.50.

SpringWorks Therapeutics Trading Down 0.0 %

Shares of NASDAQ SWTX opened at $32.28 on Monday. The firm has a market cap of $2.39 billion, a P/E ratio of -6.28 and a beta of 0.79. The business’s 50 day moving average is $37.11 and its 200-day moving average is $40.60. SpringWorks Therapeutics, Inc. has a 1-year low of $18.00 and a 1-year high of $53.92.

SpringWorks Therapeutics (NASDAQ:SWTX) last posted its earnings results on Wednesday, August 7th. The company reported ($0.54) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.12) by $0.58. The firm had revenue of $59.73 million for the quarter, compared to analyst estimates of $34.42 million. During the same period in the prior year, the business posted ($1.25) EPS. The firm’s quarterly revenue was up 59732900.0% compared to the same quarter last year. Analysts forecast that SpringWorks Therapeutics, Inc. will post -3.36 EPS for the current year.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.